Saturday 17 October 2026
Export NGNE’s income statement to Excel — free account
Neurogene Inc.
NGNE Healthcare Biotechnology
Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00. In the quarter to June 2026, EPS fell 45.7%, free cash flow fell 23.0% and total debt fell 66.7%, each against the same quarter a year earlier.
23.27
0.68
−2.84%
Follow NGNE
Neurogene Inc. (NGNE) P/E ratio
Neurogene Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 6.8× (November 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2024 | 0.0× | — |
| Jun 2018 | 0.0× | — |
Against its own ten years
Low 0.0×
High 6.8×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RGNX REGENXBIO Inc. compare | n/m |
| MNPR Monopar Therapeutics Inc. compare | n/m |
| NGNE Neurogene Inc. | n/m |
| ALT Altimmune, Inc. compare | n/m |
| CBIO Crescent Biopharma, Inc. compare | n/m |
| ENTX Entera Bio Ltd. compare | n/m |
| ALLO Allogene Therapeutics, Inc. compare | n/m |
| ARVN Arvinas, Inc. compare | 53.6× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)